Accentuating the caveat emptor perspective with critical commentary on financial disclosure. I adopt a skeptical persona and look for chinks in the teflon coating of financial disclosure. My job is to identify financial warts. Perhaps a Black Swan. Disclosure: I do not hold positions in stocks mentioned for three trading days before or after blog post.
Thursday, February 02, 2006
Aspreva Pharmaceuticals Drip Drip Drip (Nasdaq:ASPL)
Aspreva Pharmaceuticals (Nasdaq:ASPL, TSX:ASV) knows how to tease the investment community with the drip method. They announce on Feb 1 something called preliminary results and let some sales figures out. In the same release they announce that on Feb 8 full results will be released. Hmmm talk about seeding or is it juicing the ball.